Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Phase 2 Active not recruiting 8 enrolled Irada Ibrahim-zada

NaSequentialOpen-labelTreatment

Summary

The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.

Timeline

Start: 2022-02-18
Primary completion: 2025-12-09
Completion: 2026-06-09

Publications

McDonald HG, Cassim EB, Harper MM, Burke EE, Marcinkowski EF, Cavnar MJ, Pandalai PK, Kim J. The Development of Investigator-Initiated Clinical Trials in Surgical Oncology. Surg Oncol Clin N Am. 2023 Jan;32(1):13-25. doi: 10.1016/j.soc.2022.07.003. Epub 2022 Nov 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anastrozole	Other / unclassified	1 mg	Oral
Subject	Exemestane	Small molecule	25 mg	Oral
Subject	Letrozole	Other / unclassified	2.5 mg	Oral
Subject	Tamoxifen	Small molecule	20 mg	Oral

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Summary

Timeline

Publications

Drugs

Indications